[go: up one dir, main page]

NO20020684L - 3(5)-aminopyrazolderivater, fremgangsmåtet for deres fremstilling og deres anvendelse som antitumormidler - Google Patents

3(5)-aminopyrazolderivater, fremgangsmåtet for deres fremstilling og deres anvendelse som antitumormidler

Info

Publication number
NO20020684L
NO20020684L NO20020684A NO20020684A NO20020684L NO 20020684 L NO20020684 L NO 20020684L NO 20020684 A NO20020684 A NO 20020684A NO 20020684 A NO20020684 A NO 20020684A NO 20020684 L NO20020684 L NO 20020684L
Authority
NO
Norway
Prior art keywords
preparation
antitumor agents
aminopyrazole derivatives
aminopyrazole
derivatives
Prior art date
Application number
NO20020684A
Other languages
English (en)
Norwegian (no)
Other versions
NO20020684D0 (no
Inventor
Paolo Pevarello
Paolo Orsini
Gabriella Traquandi
Mario Varasi
Edward L Fritzen
Martha A Warpehoski
Betsy S Pierce
Maria Gabriella Brasca
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of NO20020684D0 publication Critical patent/NO20020684D0/no
Publication of NO20020684L publication Critical patent/NO20020684L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/16—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20020684A 1999-08-12 2002-02-11 3(5)-aminopyrazolderivater, fremgangsmåtet for deres fremstilling og deres anvendelse som antitumormidler NO20020684L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37283199A 1999-08-12 1999-08-12
PCT/US2000/006699 WO2001012189A1 (en) 1999-08-12 2000-05-05 3(5)-amino-pyrazole derivatives, process for their preparation and their use as antitumor agents

Publications (2)

Publication Number Publication Date
NO20020684D0 NO20020684D0 (no) 2002-02-11
NO20020684L true NO20020684L (no) 2002-04-03

Family

ID=23469802

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20020684A NO20020684L (no) 1999-08-12 2002-02-11 3(5)-aminopyrazolderivater, fremgangsmåtet for deres fremstilling og deres anvendelse som antitumormidler

Country Status (35)

Country Link
US (2) US7034049B1 (et)
EP (1) EP1202733B1 (et)
JP (1) JP2003507329A (et)
KR (1) KR20020060160A (et)
CN (1) CN1373662A (et)
AP (1) AP2002002442A0 (et)
AR (1) AR026122A1 (et)
AT (1) ATE305782T1 (et)
AU (1) AU4971400A (et)
BG (1) BG106480A (et)
BR (1) BR0013143A (et)
CA (1) CA2383555C (et)
CZ (1) CZ2002422A3 (et)
DE (1) DE60023012T2 (et)
DK (1) DK1202733T3 (et)
EA (1) EA005373B1 (et)
EE (1) EE200200065A (et)
ES (1) ES2249270T3 (et)
GE (1) GEP20053476B (et)
HK (1) HK1046866A1 (et)
HR (1) HRP20020128A2 (et)
HU (1) HUP0203542A3 (et)
IL (1) IL147923A0 (et)
IS (1) IS6265A (et)
MA (1) MA25493A1 (et)
MX (1) MXPA02001498A (et)
NO (1) NO20020684L (et)
NZ (1) NZ517237A (et)
OA (1) OA12046A (et)
PE (1) PE20010130A1 (et)
PL (1) PL353455A1 (et)
SK (1) SK1812002A3 (et)
WO (1) WO2001012189A1 (et)
YU (1) YU9602A (et)
ZA (1) ZA200201511B (et)

Families Citing this family (160)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9901691D0 (en) 1999-01-26 1999-03-17 Cerebrus Ltd Chemical compounds
EA005373B1 (ru) * 1999-08-12 2005-02-24 Фармация Италия С.П.А. Производные 3(5)-аминопиразола, способ их получения и их применение в качестве противоопухолевых средств
EP1268472B1 (en) 2000-02-07 2004-10-13 Bristol-Myers Squibb Company 3-aminopyrazole inhibitors of cyclin dependent kinases
WO2001081348A1 (en) 2000-04-25 2001-11-01 Bristol-Myers Squibb Company USE OF 5-THIO-, SULFINYL- AND SULFONYLPYRAZOLO[3,4-b]-PYRIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS
DE10037310A1 (de) * 2000-07-28 2002-02-07 Asta Medica Ag Neue Indolderivate und deren Verwendung als Arzneimittel
NZ523656A (en) * 2000-08-31 2004-11-26 Pfizer Prod Inc Pyrazole derivatives and their use as protein kinase inhibitors
US20020103185A1 (en) * 2000-08-31 2002-08-01 Sanner Mark A. Pyrazole derivatives
AU2002215053A1 (en) * 2000-11-27 2002-06-24 Pharmacia Italia S.P.A. Phenylacetamido- pyrazole derivatives and their use as antitumor agents
US6455559B1 (en) * 2001-07-19 2002-09-24 Pharmacia Italia S.P.A. Phenylacetamido-pyrazole derivatives, process for their preparation and their use as antitumor agents
US20040116497A1 (en) * 2001-01-26 2004-06-17 Gabriella Traquandi Chromane derivatives, process for their preparation and their use as antitumor agents
CN1280289C (zh) * 2001-03-02 2006-10-18 弗·哈夫曼-拉罗切有限公司 用作ip拮抗剂的烷氧基羰基氨基杂芳基羧酸衍生物
SE0100902D0 (sv) * 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
SE0100903D0 (sv) * 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
US6787555B2 (en) 2001-04-30 2004-09-07 The Procter & Gamble Company Triazole compounds useful in treating diseases associated with unwanted cytokine activity
US6727364B2 (en) 2001-04-30 2004-04-27 The Procter & Gamble Company Triazole compounds useful in treating diseases associated with unwanted cytokine activity
JP2004535411A (ja) 2001-05-25 2004-11-25 ブリストルーマイヤーズ スクイブ カンパニー マトリックスメタロプロテナーゼ及び／またはＴＮＦ−α転換酵素（ＴＡＣＥ）の阻害剤としてのヒダントイン及び関連複素環化合物
DE10148618B4 (de) * 2001-09-25 2007-05-03 Schering Ag Substituierte N-(1,4,5,6-Tetrahydro-cyclopentapyrazol-3-yl)-Derivate, deren Herstellung und Verwendung als Arzneimittel
DE10148617A1 (de) * 2001-09-25 2003-04-24 Schering Ag Substituierte N-(1,4,5,6-Tetrahydro-cyclopentapyrazol-3-yl)-Derivate, deren Herstellung und Verwendung als Arzneimittel
US7087768B2 (en) * 2001-09-27 2006-08-08 Equispharm Co., Ltd. Fumagillol derivatives and preparing method thereof
SE0103710D0 (sv) 2001-11-07 2001-11-07 Astrazeneca Ab Compounds
WO2003046207A2 (en) * 2001-11-27 2003-06-05 Fred Hutchinson Cancer Research Center Methods for inhibiting deacetylase activity
SE0202539D0 (sv) 2002-08-27 2002-08-27 Astrazeneca Ab Compounds
GB0221246D0 (en) * 2002-09-13 2002-10-23 Astrazeneca Ab Compounds
US6593477B1 (en) 2002-10-29 2003-07-15 Eastman Kodak Company Synthesis of 3-acylaminopyrazoles
NZ540799A (en) * 2002-12-10 2008-09-26 Virochem Pharma Inc Compounds and methods for the treatment or prevention of flavivirus infections
UA81790C2 (uk) 2002-12-19 2008-02-11 Фармация Италия С.П.А. Заміщені піролопіразольні похідні як інгібітори кінази
WO2004063194A1 (en) * 2003-01-06 2004-07-29 Eli Lilly And Company Heteroaryl compounds
PL378117A1 (pl) * 2003-02-11 2006-03-06 Prosidion Limited Tricyklopodstawione związki amidowe
CN1791402A (zh) * 2003-03-27 2006-06-21 麦克公司 治疗眼高压的眼科组合物
SE0301446D0 (sv) 2003-05-16 2003-05-16 Astrazeneca Ab New Compounds
BRPI0410563B8 (pt) 2003-05-22 2021-05-25 Nerviano Medical Sciences Srl compostos de pirazol-quinazolina, seus processos de preparação e composições farmacêuticas
EP1633350B1 (en) 2003-06-05 2012-10-03 Elan Pharmaceuticals, Inc. Acylated amino acid amidyl pyrazoles and related compounds
US7141568B2 (en) 2003-07-09 2006-11-28 Pfizer Italia S.R.L. Pyrrolo[3,4-c]pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
SG146624A1 (en) 2003-09-11 2008-10-30 Kemia Inc Cytokine inhibitors
DE602005016775D1 (de) * 2004-01-16 2009-11-05 Wyeth Corp Heterocyclische, ein azol enthaltende sulfonamidinhibitoren der beta-amyloid-produktion
WO2005072731A1 (en) * 2004-01-29 2005-08-11 X-Ceptor Therapeutics, Inc. 3-phenyl-n- ((1, 3, 4) thiadiazol-2-yl) -acrylamide derivatives and related compounds as modulators of estrogen-related receptors for the treatment of e.g. cancer, rheumatoid arthritis or neurological disorders
US7977322B2 (en) 2004-08-20 2011-07-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
WO2005075435A1 (en) * 2004-01-30 2005-08-18 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
TW200526204A (en) 2004-02-03 2005-08-16 Pharmacia Italia Spa 1h-thieno[2,3-c]pyrazole derivatives useful as kinase inhibitors
WO2005118543A1 (ja) * 2004-06-03 2005-12-15 Ono Pharmaceutical Co., Ltd. キナーゼ阻害薬およびその用途
US7648992B2 (en) 2004-07-05 2010-01-19 Astrazeneca Ab Hydantoin derivatives for the treatment of obstructive airway diseases
SE0401762D0 (sv) * 2004-07-05 2004-07-05 Astrazeneca Ab Novel compounds
KR101066882B1 (ko) * 2004-12-03 2011-09-26 트랜스테크 파르마, 인크. 헤테로방향족 글루코키나제 활성화제
SE0403086D0 (sv) 2004-12-17 2004-12-17 Astrazeneca Ab Compounds
SE0403085D0 (sv) 2004-12-17 2004-12-17 Astrazeneca Ab Novel componds
US7361672B2 (en) 2004-12-23 2008-04-22 Hoffmann-La Roche Inc. Heteroarylacetamide inhibitors of factor Xa
FR2880540B1 (fr) * 2005-01-13 2008-07-11 Aventis Pharma Sa Utilisation de derives de la purine comme inhibiteurs de la proteine hsp90
WO2007037898A2 (en) * 2005-08-29 2007-04-05 Housey Pharmaceuticals Inc Theramutein modulators
US7514439B2 (en) * 2005-07-11 2009-04-07 Mitsubishi Tanabe Pharma Corporation Oxime derivative and preparations thereof
JP5303271B2 (ja) 2005-07-19 2013-10-02 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ キナーゼ阻害剤として有用な１Ｈ−チエノ［２，３−ｃ］ピラゾール化合物
TW200736227A (en) 2005-12-23 2007-10-01 Astrazeneca Ab New compounds III
US20070203224A1 (en) * 2006-01-09 2007-08-30 University Of Southern California Small-molecules for treating cancer and abnormal cell proliferation disorders
WO2007095383A2 (en) * 2006-02-15 2007-08-23 Myriad Genetics, Inc. Prodrugs
UY30183A1 (es) * 2006-03-02 2007-10-31 Astrazeneca Ab Derivados de quinolina
US8211925B2 (en) * 2006-04-28 2012-07-03 Transtech Pharma, Inc. Benzamide glucokinase activators
WO2007129052A1 (en) * 2006-05-03 2007-11-15 Astrazeneca Ab Pyrazole derivatives and their use as pi3k inhibitors
EP2049106A2 (en) * 2006-07-14 2009-04-22 Astex Therapeutics Limited Pharmaceutical combinations
TWI433839B (zh) 2006-08-11 2014-04-11 Neomed Inst 新穎的苯并咪唑衍生物290
TW200831488A (en) * 2006-11-29 2008-08-01 Astrazeneca Ab Novel compounds
US7737149B2 (en) 2006-12-21 2010-06-15 Astrazeneca Ab N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof
WO2008084873A1 (ja) * 2007-01-10 2008-07-17 Mitsubishi Tanabe Pharma Corporation オキシム誘導体
JP5207981B2 (ja) * 2007-01-10 2013-06-12 田辺三菱製薬株式会社 ヒドラゾン誘導体
US8940900B2 (en) * 2007-02-28 2015-01-27 Advinus Therapeutics Private Limited 2,2,2-tri-substituted acetamide derivatives as glucokinase activators, their process and pharmaceutical application
KR100923540B1 (ko) * 2007-11-23 2009-10-27 한국과학기술연구원 5-아실하이드라진카르보닐-3,4-디치환 피라졸 유도체 및이의 제조방법
WO2009153592A1 (en) * 2008-06-19 2009-12-23 Astrazeneca Ab Pyrazole compounds 436
PL2325181T3 (pl) * 2008-07-10 2017-09-29 General Incorporated Association Pharma Valley Project Supporting Organization Inhibitor STAT3 zawierający jako składnik aktywny pochodną chinolinokarboksyamidu
JP5683462B2 (ja) 2008-07-24 2015-03-11 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ オーロラキナーゼ阻害剤および抗増殖剤を含む治療用組み合わせ
US20100160322A1 (en) 2008-12-04 2010-06-24 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8557983B2 (en) 2008-12-04 2013-10-15 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
EP3101019A1 (en) * 2008-12-05 2016-12-07 AbbVie Inc. Sulfonamide derivatives as bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
US8563735B2 (en) 2008-12-05 2013-10-22 Abbvie Inc. Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
US8586754B2 (en) 2008-12-05 2013-11-19 Abbvie Inc. BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
BRPI1006896B1 (pt) * 2009-01-30 2022-05-24 Novartis Ag Cloridrato de n-{(1s)-2-amino-1-[(3-fluorfenil)metil]etil}-5-cloro-4-(4-cloro-1-metil-1h- pirazol-5-il)-2-tiofenocarboxamida cristalino, composição farmacêutica compreendendo o mesmo e uso do dito composto para tratar ou diminuir a gravidade de câncer e artrite
US20120045459A1 (en) * 2009-05-05 2012-02-23 Van Andel Research Institute Methods for Treating Autophagy-Related Disorders
EP2467137A1 (en) * 2009-08-19 2012-06-27 Ambit Biosciences Corporation Biaryl compounds and methods of use thereof
US9062076B2 (en) 2009-10-22 2015-06-23 Fibrotech Therapeutics Pty Ltd Fused ring analogues of anti-fibrotic agents
US20120316171A1 (en) * 2009-11-05 2012-12-13 Tamas Oravecz Tryptophan Hydroxylase Inhibitors for the Treatment of Cancer
KR101955691B1 (ko) 2010-03-30 2019-03-07 베르선 코포레이션 트롬빈 억제제로서의 다중치환된 방향족 화합물
EP2576532B1 (en) 2010-06-07 2018-07-18 Novomedix, LLC Furanyl compounds and the use thereof
WO2011158108A2 (en) 2010-06-16 2011-12-22 Purdue Pharma L.P. Aryl substituted indoles and the use thereof
KR101825773B1 (ko) * 2010-11-03 2018-02-05 다우 아그로사이언시즈 엘엘씨 살충 조성물 및 이에 관련된 방법
JP6097998B2 (ja) * 2010-12-16 2017-03-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ロイコトリエン生成のビアリールアミドインヒビター
MX342873B (es) 2010-12-17 2016-10-17 Nerviano Medical Sciences S R L * Derivados de pirazolo-quinazolina sustituidos como inhibidores de cinasa.
FR2978441A1 (fr) * 2011-07-25 2013-02-01 Diverchim Nouveaux analogues de ceramides, leurs procedes de preparation et leurs applications dans les compositions pharmaceutiques et cosmetiques
AR087701A1 (es) * 2011-08-31 2014-04-09 Japan Tobacco Inc Derivados de pirazol con actividad inhibidora de sglt1
US9056867B2 (en) * 2011-09-16 2015-06-16 Novartis Ag N-substituted heterocyclyl carboxamides
MX355431B (es) 2011-10-26 2018-04-18 Dow Agrosciences Llc Composiciones plaguicidas y procesos relacionados con dichas composiciones.
US9708288B2 (en) 2012-04-27 2017-07-18 Dow Agrosciences Llc Pesticidal compositions and processes related thereto
US9282739B2 (en) 2012-04-27 2016-03-15 Dow Agrosciences Llc Pesticidal compositions and processes related thereto
EP2852284A4 (en) 2012-04-27 2016-05-04 Dow Agrosciences Llc PESTICIDAL COMPOSITIONS AND CORRESPONDING METHODS
US20140179712A1 (en) 2012-12-21 2014-06-26 Astrazeneca Ab Pharmaceutical formulation of n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2h-pyrazol-3-yl]-4-[(3r,5s)-3,5-dimethylpiperazin-1-yl]benzamide
CN103936637B (zh) * 2013-01-18 2016-04-06 北京大学 E-3,4-二羟苯乙烯基亚砜类化合物的制备方法及其作为神经保护药物的应用
MA38394B1 (fr) 2013-03-15 2018-04-30 Glaxosmithkline Ip Dev Ltd Dérivés pyridine utilisés comme inhibiteurs de la kinase réarrangée au cours de la transfection (ret)
PE20151538A1 (es) 2013-03-15 2015-11-18 Glaxosmithkline Ip Dev Ltd Nuevos compuestos como inhibidores de reorganizado durante la transfeccion (ret)
BR112015022340A2 (pt) 2013-03-15 2017-07-18 Verseon Corp método para tratamento ou prevenção de uma doença ou distúrbio relacionado à calicreína em um sujeito, composto, e, composição farmacêutica
RU2015144193A (ru) 2013-03-15 2017-04-24 Версеон Корпорейшн Галогенпиразолы в качестве ингибиторов тромбина
WO2014170350A1 (en) * 2013-04-17 2014-10-23 Albert Ludwigs Universität Freiburg Compounds for use as bromodomain inhibitors
CN103265535B (zh) * 2013-05-14 2015-06-17 浙江医药高等专科学校 抗肿瘤化合物、其制备方法和用途
SG11201601341QA (en) * 2013-08-30 2016-03-30 Ambit Biosciences Corp Biaryl acetamide compounds and methods of use thereof
CA2925952A1 (en) 2013-10-17 2015-04-23 Dow Agrosciences Llc Processes for the preparation of pesticidal compounds
WO2015058020A1 (en) 2013-10-17 2015-04-23 Dow Agrosciences Llc Processes for the preparation of pesticidal compounds
KR20160072154A (ko) 2013-10-17 2016-06-22 다우 아그로사이언시즈 엘엘씨 살충성 화합물의 제조 방법
MX2016004940A (es) 2013-10-17 2016-06-28 Dow Agrosciences Llc Proceso para la preparacion de compuestos plaguicidas.
US9044017B2 (en) 2013-10-17 2015-06-02 Dow Agrosciences Llc Processes for the preparation of pesticidal compounds
CA2925873A1 (en) 2013-10-17 2015-04-23 Dow Agrosciences Llc Processes for the preparation of pesticidal compounds
CA2925953C (en) 2013-10-17 2021-11-02 Dow Agrosciences Llc Processes for the preparation of pesticidal compounds
JP2016534086A (ja) 2013-10-22 2016-11-04 ダウ アグロサイエンシィズ エルエルシー 相乗的有害生物防除組成物および関連する方法
WO2015061142A1 (en) 2013-10-22 2015-04-30 Dow Agrosciences Llc Synergistic pesticidal compositions and related methods
AU2014340412B2 (en) 2013-10-22 2017-04-20 Dow Agrosciences Llc Synergistic pesticidal compositions and related methods
CN105658059A (zh) 2013-10-22 2016-06-08 美国陶氏益农公司 杀虫组合物和与其相关的方法
WO2015061163A1 (en) 2013-10-22 2015-04-30 Dow Agrosciences Llc Pesticidal compositions and related methods
CN105828613A (zh) 2013-10-22 2016-08-03 美国陶氏益农公司 协同杀虫组合物和与其相关的方法
MX2016005308A (es) 2013-10-22 2016-08-08 Dow Agrosciences Llc Composiciones pesticidas sinergicas y metodos relacionados.
TW201517797A (zh) 2013-10-22 2015-05-16 Dow Agrosciences Llc 協同性殺蟲組成物及相關方法（十一）
AR098100A1 (es) 2013-10-22 2016-05-04 Dow Agrosciences Llc Composiciones plaguicidas y los métodos relacionados
KR20160074634A (ko) 2013-10-22 2016-06-28 다우 아그로사이언시즈 엘엘씨 상승작용적 살충 조성물 및 관련 방법
WO2015061165A1 (en) 2013-10-22 2015-04-30 Dow Agrosciences Llc Pesticidal compositions and related methods
JP2016535022A (ja) 2013-10-22 2016-11-10 ダウ アグロサイエンシィズ エルエルシー 農薬組成物および関連する方法
NZ719776A (en) 2013-10-22 2017-06-30 Dow Agrosciences Llc Synergistic pesticidal compositions and related methods
RU2016119368A (ru) 2013-10-22 2017-11-28 ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи Синергетические пестицидные композиции и связанные с ними способы
AR098088A1 (es) 2013-10-22 2016-05-04 Dow Agrosciences Llc Composiciones plaguicidas sinérgicas y métodos relacionados
JP2016536304A (ja) 2013-10-22 2016-11-24 ダウ アグロサイエンシィズ エルエルシー 相乗的有害生物防除組成物および関連する方法
MX2016005319A (es) 2013-10-22 2016-08-12 Dow Agrosciences Llc Composiciones pesticidas y metodos relacionados.
WO2015143653A1 (en) * 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF
BR112017000293A2 (pt) 2014-07-31 2017-10-31 Dow Agrosciences Llc processo para a preparação de 3-(3-cloro-1h-pirazol-1-il)piridina
KR20170039121A (ko) 2014-07-31 2017-04-10 다우 아그로사이언시즈 엘엘씨 3-(3-클로로-1h-피라졸-1-일)피리딘의 제조 방법
EP3186229A4 (en) 2014-07-31 2018-01-10 Dow AgroSciences LLC Process for the preparation of 3-(3-chloro-1h-pyrazol-1-yl)pyridine
JP2017525703A (ja) 2014-08-19 2017-09-07 ダウ アグロサイエンシィズ エルエルシー ３−（３−クロロ−１ｈ−ピラゾール−１−イル）ピリジンの調製方法
SG11201701694QA (en) 2014-09-10 2017-04-27 Glaxosmithkline Ip Dev Ltd Pyridone derivatives as rearranged during transfection (ret) kinase inhibitors
DK3191449T3 (da) 2014-09-10 2020-08-03 Glaxosmithkline Ip Dev Ltd Forbindelser som ret- (rearranged during transfection) hæmmere
BR112017004613A2 (pt) 2014-09-12 2017-12-05 Dow Agrosciences Llc processo para a preparação de 3-(3-cloro-1h-pirazol-1-il)piridina
MX2017003624A (es) 2014-09-17 2017-07-13 Verseon Corp Compuestos de piridona sustituida con pirazolilo como inhibidores de serina proteasas.
GB201416513D0 (en) * 2014-09-18 2014-11-05 Astex Therapeutics Ltd And Cancer Res Technology Ltd Pharmaceutical compounds
JP2018506563A (ja) 2015-02-27 2018-03-08 ヴァーセオン コーポレイション セリンプロテアーゼ阻害剤としての置換ピラゾール化合物
CA2978170C (en) 2015-03-09 2024-02-27 Aurigene Discovery Technologies Limited Pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives as cdk inhibitors
AU2016258192B2 (en) 2015-05-06 2021-07-29 Leidos Biomedical Research, Inc. K-Ras modulators
KR102691467B1 (ko) 2015-06-04 2024-08-02 오리진 온콜로지 리미티드 Cdk 억제제로서의 치환된 헤테로사이클릴 유도체
EP4063360A1 (en) * 2016-08-12 2022-09-28 Athenex, Inc. Biaryl compositions and methods for modulating a kinase cascade
EP3562807B1 (en) 2016-12-29 2022-08-03 Corteva Agriscience LLC Processes for the preparation of pesticidal compounds
US10233155B2 (en) 2016-12-29 2019-03-19 Dow Agrosciences Llc Processes for the preparation of pesticide compounds
KR20190098204A (ko) * 2016-12-29 2019-08-21 엔요 파마 항바이러스제로서의 티오펜 유도체
SG11201907139UA (en) 2017-02-03 2019-09-27 Certa Therapeutics Pty Ltd Anti-fibrotic compounds
CA3056886A1 (en) 2017-03-21 2018-09-27 Arbutus Biopharma Corporation Substituted dihydroindene-4-carboxamides and analogs thereof, and methods using same
AU2018255413A1 (en) 2017-04-20 2019-12-05 Leidos Biomedical Research, Inc. K-Ras modulators
KR20200104873A (ko) 2017-12-06 2020-09-04 린 바이오사이언스, 피티와이 엘티디. 튜불린 억제제
US11472774B2 (en) 2018-02-01 2022-10-18 The University Of Sydney Anti-cancer compounds
CA3095987A1 (en) * 2018-04-04 2019-10-10 Aurigene Discovery Technologies Limited Substituted pyrazole derivatives as selective cdk12/13 inhibitors
CN114040760B (zh) 2018-12-31 2025-05-09 拜欧米富士恩公司 Menin-mll相互作用的不可逆抑制剂
US11174263B2 (en) 2018-12-31 2021-11-16 Biomea Fusion, Inc. Inhibitors of menin-MLL interaction
CA3254823A1 (en) * 2020-01-29 2025-02-26 Foghorn Therapeutics Inc. HETEROCYCLIC COMPOUNDS USEFUL FOR MODULATING BAF COMPLEXES
CN111793034B (zh) * 2020-07-24 2021-11-19 华中科技大学 苯并咪唑盐衍生物与制备抗肿瘤药物的应用
EP4229037A2 (en) * 2020-10-16 2023-08-23 CeMM - Forschungszentrum für Molekulare Medizin GmbH Heterocyclic cullin ring ubiquitin ligase compounds and uses thereof
WO2022135442A1 (zh) * 2020-12-22 2022-06-30 上海拓界生物医药科技有限公司 Cdk2抑制剂及其制备方法
EP4384179A1 (en) 2021-08-11 2024-06-19 Biomea Fusion, Inc. Covalent inhibitors of menin-mll interaction for diabetes mellitus
JP2024534014A (ja) 2021-08-20 2024-09-18 バイオメア フュージョン，インコーポレイテッド 癌の処置のための不可逆的メニン－ＭＬＬ阻害剤、Ｎ－［４－［４－（４－モルホリニル）－７Ｈ－ピロロ［２，３－ｄ］ピリミジン－６－イル］フェニル］－４－［［３（Ｒ）－［（１－オキソ－２－プロペン－１－イル）アミノ］－１－ピペリジニル］メチル］－２－ピリジンカルボキサミドの結晶形態
JP2024545132A (ja) * 2021-12-10 2024-12-05 プロシーナ バイオサイエンシーズ リミテッド Ｄｙｒｋ１ａ阻害剤としての複素環化合物
WO2023203174A1 (en) * 2022-04-20 2023-10-26 Proxygen Gmbh Heterocyclic cullin ring ubiquitin ligase compounds and uses thereof
WO2024155710A1 (en) 2023-01-18 2024-07-25 Biomea Fusion, Inc. Crystalline forms of n-[4-[4-(4-morpholinyl)-7h-pyrrolo[2,3-d]pyrimidin-6- yl]phenyl]-4-[[3(r)-[(l-oxo-2-propen-l-yl)amino]-l-piperidinyl]methyl]-2-pyridinecarboxamide as a covalent inhibitor of menin-mll interaction
CN116496151B (zh) * 2023-04-26 2024-08-23 长沙医学院 一种利用Catellani策略制备芴酮衍生物的方法
CN118221668A (zh) * 2024-03-19 2024-06-21 华南农业大学 一种含2-氨基-1,3,4-噻二唑的吲哚美辛衍生物及其制备方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5162360A (en) 1991-06-24 1992-11-10 Warner-Lambert Company 2-heteroatom containing urea and thiourea ACAT inhibitors
AU700964B2 (en) 1994-11-10 1999-01-14 Cor Therapeutics, Inc. Pharmaceutical pyrazole compositions useful as inhibitors of protein kinases
US6043246A (en) 1996-12-03 2000-03-28 Banyu Pharmaceutical Co., Ltd. Urea derivatives
CA2288787A1 (en) 1997-05-22 1998-11-26 G.D. Searle And Co. Pyrazole derivatives as p38 kinase inhibitors
HUP0004426A3 (en) 1997-12-22 2001-07-30 Bayer Corp Pittsburgh Inhibition of raf kinase using aryl and heteroaryl substituted heterocyclic ureas
EP1041982B1 (en) 1997-12-22 2011-10-19 Bayer HealthCare LLC INHIBITION OF p38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS
EA005373B1 (ru) * 1999-08-12 2005-02-24 Фармация Италия С.П.А. Производные 3(5)-аминопиразола, способ их получения и их применение в качестве противоопухолевых средств
US6455559B1 (en) * 2001-07-19 2002-09-24 Pharmacia Italia S.P.A. Phenylacetamido-pyrazole derivatives, process for their preparation and their use as antitumor agents

Also Published As

Publication number Publication date
HUP0203542A3 (en) 2003-07-28
WO2001012189A1 (en) 2001-02-22
HK1046866A1 (zh) 2003-01-30
BR0013143A (pt) 2002-06-11
CN1373662A (zh) 2002-10-09
WO2001012189A8 (en) 2001-08-02
ZA200201511B (en) 2003-05-28
DE60023012D1 (de) 2006-02-16
IS6265A (is) 2002-02-11
EA200200248A1 (ru) 2002-08-29
JP2003507329A (ja) 2003-02-25
NZ517237A (en) 2004-02-27
AR026122A1 (es) 2003-01-29
CZ2002422A3 (cs) 2002-11-13
OA12046A (en) 2006-05-02
SK1812002A3 (en) 2003-02-04
AU4971400A (en) 2001-03-13
US6218418B1 (en) 2001-04-17
ATE305782T1 (de) 2005-10-15
KR20020060160A (ko) 2002-07-16
PL353455A1 (en) 2003-11-17
DK1202733T3 (da) 2005-10-31
PE20010130A1 (es) 2001-02-01
MA25493A1 (fr) 2002-07-01
YU9602A (sh) 2004-11-25
EA005373B1 (ru) 2005-02-24
DE60023012T2 (de) 2006-07-20
GEP20053476B (en) 2005-03-25
CA2383555A1 (en) 2001-02-22
ES2249270T3 (es) 2006-04-01
HRP20020128A2 (en) 2003-04-30
HUP0203542A2 (en) 2003-05-28
CA2383555C (en) 2009-02-17
NO20020684D0 (no) 2002-02-11
IL147923A0 (en) 2002-08-14
EE200200065A (et) 2003-04-15
EP1202733A1 (en) 2002-05-08
EP1202733A4 (en) 2003-05-14
US7034049B1 (en) 2006-04-25
AP2002002442A0 (en) 2002-03-31
BG106480A (en) 2002-09-30
MXPA02001498A (es) 2003-07-21
EP1202733B1 (en) 2005-10-05

Similar Documents

Publication Publication Date Title
NO20020684L (no) 3(5)-aminopyrazolderivater, fremgangsmåtet for deres fremstilling og deres anvendelse som antitumormidler
NO20020687L (no) 3(5)-ureido-pyrazolderivater, fremgangsmåte for fremstilling av disse og deres anvendelse som antitumormidler
NO20012058D0 (no) 2-ureido-tiazolderivater, fremgangsmåte for deres fremstilling og anvendelse som antitumormidler
NO20012057D0 (no) 2-amino-tiazolderivater, fremgangsmåte for deres fremstilling og anvendelse som antitumormidler
NO20015477D0 (no) 4,5,6,7-tetrahydroindazol-derivater som anti-tumor midler
NO963506D0 (no) 4-Heterocyklyl-substituerte kinazolin-derivater, fremgangsmåte for fremstilling derav og deres anvendelse som anti-kreftmidler
DK1204649T3 (da) Arylmethylcarbonylaminothiazolderivater og deres anvendelse som antitumormidler
IL160707A0 (en) 1, 8-naphthyridine derivatives as antidiabetics
NO20011216L (no) Azetidinderivater, deres fremstilling og medikamenter inneholdende forbindelsene
PT1218378E (pt) Derivados de terc-butil-(7-metil-imidazo-¬1,2-a|-piridin-3-il)-amina
NO20013671L (no) Substituerte bisycliske derivater nyttige som anticancer midler
NO993003D0 (no) Sulfonamid-derivater, fremgangsmÕte for deres fremstilling og deres anvendelse som medikamenter
NO20024175D0 (no) Azetidinderivater, deres fremstilling og farmasöytiske forbindelser inneholdende de samme
NO20016038L (no) Benzenderivater, fremgangsmåte for deres fremstilling og farmasöytiske preparater inneholdende de samme
DK1083171T3 (da) Pyrazolinderivater, deres fremstilling og anvendelse som medikamenter
DK1095025T3 (da) Benzimidazoler, deres fremstilling og deres anvendelse som lægemidler
EE04721B1 (et) Fenüülksantiini derivaadid, nende valmistamismeetodid ja kasutamine
NO20005146L (no) Tienylazolylalkoksyetanaminer, deres fremstilling og deres anvendelse som medikamenter
NO20040210L (no) Fenylacetamido-tiazolderivater, fremgangsmate for deres fremstilling og deres anvendelse som antitumormidler
NO985307D0 (no) Distamycinderivater, fremgangsmÕte for deres fremstilling, og deres anvendelse som antitumor- og antivirale midler
NO20010219L (no) Polycykliske tiazolidin-2-ylidenaminer, fremgangsmÕte for deres fremstilling og deres anvendelse som legemiddel
DK1235809T3 (da) Substituerede 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazociner og deres anvendelse som lægemidler
DK1124810T3 (da) 2-amino-thiazolderivater, fremgangsmåde til deres fremstilling og deres anvendelse som antitumormidler
DK1177185T3 (da) 4,5,6,7-tetrahydroindazolderivater som antitumormidler
DK1072266T3 (da) Thienylazolylalkoxyethanaminer, deres fremstilling og deres anvendelse som lægemidler

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application